Search

Objective: Although early-stage lung cancer patients are curable, the prognosis is limited and the 5-year survival rates range from 40 to 65 percent. In this study, clinicopathologic features, treatment responses and prognostic factors of non-small cell lung cancer patients treated with surgery were investigated. Methods: Seven-hundred-thirty-eight non-small cell lung cancer patients diagnosed and followed up between the years of 1999 and 2009 were evaluated retrospectively. Eighty patients who underwent surgery were included in the study. Results: There were 71 male and 9 female patients with the median age of 55 years (range, 39 to 71). Forty-six-point-three percent of the patients had squmous cell cancer and 35 % had adenocarcinoma. Thirty-one patients had stage I, 30 had stage II and 19 had stage IIIA disease. Forty-six percent of the patients had adjuvant radiotherapy and 50.7% had adjuvant chemotherapy. The median follow-up time after diagnosis was 34.2 months (range, 12 -132), the 5-year overall survival and the 5-year disease free survival rates were 45.5% and 32.8%, respectively. Performance status (p=0.024), tumor size (p=0.015), lymph node involvement (p=0.015) and anemia (p=0.001) were the prognostic factors associated with the overall survival. Stage (p=0.005), anemia(p=0.007) and adenocarcinoma subtype (p< 0.001) significantly affected the disease free survival. Conclusion: The performance status, stage, nodal involvement, presence of anemia are the prognostic factors affecting the survival in patients with non-small cell lung cancer.